In this regard, considering the oncogenic mutational statuses of KRAS and BRAF harbored in colon cancer cell lines with confirmed responsiveness to rTBL-1 (Table 1), a therapeutic approach based on blocking or inhibiting EGFR would be an ineffective strategy, since in such models, the signaling is transduced even in the absence of any upstream signals. The gene discussed is EGFR; the disease is malignant colon neoplasm.